Celularity Inc. (GXGX) |
| 10.2 2.18 (27.18%) 07-19 00:00 |
| Open: | 8.18 |
| High: | 12.58 |
| Low: | 8.07 |
| Volume: | 17,319,220 |
| Market Cap: | 1,479(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Shell Companies |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 14.69 |
| Resistance 1: | 12.58 |
| Pivot price: | 9.94 |
| Support 1: | 9.58 |
| Support 2: | 7.73 |
| 52w High: | 13.4 |
| 52w Low: | 7.73 |
GX Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any business operations and it has not generated any revenue.
Financials
| EPS | 0.000 |
| Book Value | 0.670 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -1.3 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 28 Jan 2025
Celularity amends warrant terms, secures $2.46 million funding By Investing.com - Investing.com Australia
Mon, 15 May 2023
Genting-backed biotech firm to get new investor - The Edge Malaysia
Fri, 16 Jul 2021
Celularity, clinical-stage cellular medicine company, goes public following $138 million merger - Medical Economics
Wed, 14 Jul 2021
Celularity (CELU) Is a Risky but Attractive Play After the GXGX Merger - Market Realist
Thu, 01 Jul 2021
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products - Yahoo Finance
Sun, 16 May 2021
GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal - citybiz
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
